重组人组织型纤维蛋白溶酶原激活物静脉溶栓对高龄急性脑梗死患者神经功能的影响

Effect of intravenous thrombolysis by recombinant human tissue fibrinogen activator on neurological function in elderly patients with acute cerebral infarction

目的 探讨重组人组织型纤维蛋白溶酶原激活物静脉溶栓对高龄急性脑梗死患者神经功能的影响。方法 回顾性分析60例高龄急性脑梗死患者的临床资料,根据治疗方法分为研究组(采用重组人组织型纤维蛋白溶酶原激活物静脉溶栓)与对照组(仅行常规治疗),各30例,比较2组的治疗效果。结果 治疗1、7、14d时,研究组NIHSS评分均显著低于对照组(P<0.05);发病后90d,研究组预后良好率(70.00%)显著高于对照组(43.33%)(P<0.05);2组不良事件发生率对比,差异无统计学意义(P>0.05)。结论 高龄急性脑梗死患者进行重组人组织型纤维蛋白溶酶原激活物静脉溶栓治疗,可改善神经功能及预后,且不会增大不良事件发生风险。

Objective To investigate the effect of intravenous thrombolysis by recombinant human tissue fibrinogen activator on neurological function in elderly patients with acute cerebral infarction. Methods The clinical data of 60 elderly patients with acute cerebral infarction in our hospital were retrospective analyzed. The patients were divided into study group ( n =30, intravenous thrombolysis using recombinant human tissue fibrinolysin activator) and control group ( n =30, routine treatment only) according to the treatment methods. The therapeutic effects were compared. Results The NIHSS scores of the study group at 1, 7 and 14 d of treatment were all lower than those of the control group ( P <0.05). The favorable prognosis rate in the study group was higher than that in the control group at 90 d after the onset(70.00% vs. 43.33%, P <0.05). There was no significant difference in the incidence of adverse events between the two groups ( P >0.05). Conclusion Intravenous thrombolytic therapy with recombinant human tissue fibrinolysin activator can improve neurological function and prognosis without increasing the risk of adverse events for elderly patients with acute cerebral infarction.